June 22, 2025
3 min watch
CHICAGO — On this video, Paolo F. Caimi, MD, MBA, workers doctor at Cleveland Clinic, discusses the part 2/3 WaveLINE-003 trial of sufferers with relapsed/refractory diffuse B-cell lymphoma.
Outcomes of the trial, which evaluated the efficacy and security of zilovertamab vedotin (Merck) plus rituximab (Rituxan; Genentech, Biogen) and gemcitabine-oxaliplatin, have been introduced at ASCO Annual Assembly.
Reference:
- Armand P, et al. Summary 7005. Introduced at: ASCO Annual Assembly; Could 30-June 3, 2025; Chicago.
Printed by:
Sources/Disclosures
Collapse
Supply:
Caimi PF, et al. Strengthening the strike: Novel remedy approaches in relapsed-refractory giant B-cell lymphoma. Introduced at: ASCO Annual Assembly; Could 30-June 3, 2025; Chicago.
Disclosures:
Caimi experiences no related monetary disclosures.
